FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553104455> ?p ?o ?g. }

• W2553104455 endingPage "1246" @default.
• W2553104455 startingPage "1246.1" @default.
• W2553104455 abstract "Background Over a decade has passed since the introduction of biologic therapies for autoimmune diseases. The use of biologic therapies as an adjuvant to disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of systemic autoimmune diseases is rapidly expanding, due the efficacy and safety profiles of these drugs, and the better understanding of the targets of altered immune regulation. However, infections complications after biologicals are major concerns in their use. Objectives The aim of this study is to evaluate the clinical benefit of new personalized polybacterial sublingual vaccines in patients with systemic autoimmune disease and recurrent infections. Methods An observational study in a cohort of patients with systemic autoimmune disease and recurrent respiratory tract infections (RRTI) (3 or more episodes of upper respiratory tract infection or at least 1 pneumonia episode per year) and recurrent urinary tract infections (RUTI) (3 or more UTIs per year) was carried out. All patients underwent immunization with sublingual polyvalent preparation (Bactek®, ImmunoteK S.L. Madrid, Spain) for RRTI (Staphylococcus spp., S. pneumoniae, K. pneumoniae, B. catarrhalis, H. influenzae) and RUTI (K. pneumonia, E. coli, E. faecalis, P. vulgaris). Immunological evaluation was performed at baseline and at 6- and 12-mo., including serum immunoglobulins, IgG subclasses, specific antibodies production and B and T cell subsets counts. Results Twenty-three patients (mean age, 55.52±15.69, 21 women and 2 men) were studied: rheumatoid arthritis (RA) (n=11, 47%), SLE (n=5, 22%), MCTD (n=3, 13%), psoriatic arthritis (n=1, 4.%), SLE/RA (n=1, 4%), DLE/Sjogren (n=1, 4%), cryoglobulinemia II (n=1, 4%) and Sjogren syndrome (n=1, 4%). All patients presented a decrease in RRTI and RUTI frequency at 6-mo of vaccine: RRTI decreased from 4.81±2.04 to 0.75±1.29 and RUTI from 4.56±1.59 to 0.22±0.44. An episode of pneumonia in two patients. Nine out of 23 patients (39%) showed alterations of the humoral immune response at baseline: hypogammaglobulinemia (n=6, 26%) and IgG2 subclass deficiency (n=3, 13%). Eleven of 23 (47%) disclosed a defect on specific antibody production to polysaccharide and protein stimuli, 7 (30%) with normal Ig serum levels and 5 (21%) with hypogammaglobulinemia. At baseline, 21 were on DMARDs (metotrexate in 12, 52%). The most used biologicals were anti-TNF-α monoclonal antibodies (n=9, 39%) followed by anti-CD20 (n=8, 34%) and tocilizumab (n=4, 17%). Conclusions Vaccination in immunosuppressed patients with systemic autoimmune disease and recurrent infections is a commonly missed opportunity. There is an urgent need to develop alternative strategies to prevent the overuse of antibiotics in what is called the post-antibiotic era. Our preliminary results seem to be promising in these patients, reducing the infections rates, avoiding chronic use of antibiotics and subsequent resistance and adverse effects. Disclosure of Interest None declared" @default.
• W2553104455 created "2016-11-30" @default.
• W2553104455 creator A5005259481 @default.
• W2553104455 creator A5005424221 @default.
• W2553104455 creator A5011777462 @default.
• W2553104455 creator A5015962470 @default.
• W2553104455 creator A5016910009 @default.
• W2553104455 creator A5020106561 @default.
• W2553104455 creator A5020411435 @default.
• W2553104455 creator A5028808173 @default.
• W2553104455 creator A5041835945 @default.
• W2553104455 creator A5046945106 @default.
• W2553104455 creator A5062285965 @default.
• W2553104455 creator A5077220786 @default.
• W2553104455 creator A5079860415 @default.
• W2553104455 creator A5085479328 @default.
• W2553104455 date "2016-06-01" @default.
• W2553104455 modified "2023-10-18" @default.
• W2553104455 title "AB1007 Recurrent Infection after Biologicals in Autoimmune Disease: Preliminary Results with Mucosal Vaccines Recurrent Infection after Biologicals in Autoimmune Disease: Preliminary Results with Mucosal Vaccines" @default.
• W2553104455 doi "https://doi.org/10.1136/annrheumdis-2016-eular.3725" @default.
• W2553104455 hasPublicationYear "2016" @default.
• W2553104455 type Work @default.
• W2553104455 sameAs 2553104455 @default.
• W2553104455 citedByCount "0" @default.
• W2553104455 crossrefType "journal-article" @default.
• W2553104455 hasAuthorship W2553104455A5005259481 @default.
• W2553104455 hasAuthorship W2553104455A5005424221 @default.
• W2553104455 hasAuthorship W2553104455A5011777462 @default.
• W2553104455 hasAuthorship W2553104455A5015962470 @default.
• W2553104455 hasAuthorship W2553104455A5016910009 @default.
• W2553104455 hasAuthorship W2553104455A5020106561 @default.
• W2553104455 hasAuthorship W2553104455A5020411435 @default.
• W2553104455 hasAuthorship W2553104455A5028808173 @default.
• W2553104455 hasAuthorship W2553104455A5041835945 @default.
• W2553104455 hasAuthorship W2553104455A5046945106 @default.
• W2553104455 hasAuthorship W2553104455A5062285965 @default.
• W2553104455 hasAuthorship W2553104455A5077220786 @default.
• W2553104455 hasAuthorship W2553104455A5079860415 @default.
• W2553104455 hasAuthorship W2553104455A5085479328 @default.
• W2553104455 hasConcept C126322002 @default.
• W2553104455 hasConcept C159654299 @default.
• W2553104455 hasConcept C198451711 @default.
• W2553104455 hasConcept C203014093 @default.
• W2553104455 hasConcept C2776260265 @default.
• W2553104455 hasConcept C2777575956 @default.
• W2553104455 hasConcept C2777914695 @default.
• W2553104455 hasConcept C2779075594 @default.
• W2553104455 hasConcept C71924100 @default.
• W2553104455 hasConceptScore W2553104455C126322002 @default.
• W2553104455 hasConceptScore W2553104455C159654299 @default.
• W2553104455 hasConceptScore W2553104455C198451711 @default.
• W2553104455 hasConceptScore W2553104455C203014093 @default.
• W2553104455 hasConceptScore W2553104455C2776260265 @default.
• W2553104455 hasConceptScore W2553104455C2777575956 @default.
• W2553104455 hasConceptScore W2553104455C2777914695 @default.
• W2553104455 hasConceptScore W2553104455C2779075594 @default.
• W2553104455 hasConceptScore W2553104455C71924100 @default.
• W2553104455 hasIssue "Suppl 2" @default.
• W2553104455 hasLocation W25531044551 @default.
• W2553104455 hasOpenAccess W2553104455 @default.
• W2553104455 hasPrimaryLocation W25531044551 @default.
• W2553104455 hasRelatedWork W184566536 @default.
• W2553104455 hasRelatedWork W2066486616 @default.
• W2553104455 hasRelatedWork W2070247035 @default.
• W2553104455 hasRelatedWork W2091280415 @default.
• W2553104455 hasRelatedWork W2116174976 @default.
• W2553104455 hasRelatedWork W2410978906 @default.
• W2553104455 hasRelatedWork W2946910872 @default.
• W2553104455 hasRelatedWork W3097954487 @default.
• W2553104455 hasRelatedWork W4246884729 @default.
• W2553104455 hasRelatedWork W4321509237 @default.
• W2553104455 hasVolume "75" @default.
• W2553104455 isParatext "false" @default.
• W2553104455 isRetracted "false" @default.
• W2553104455 magId "2553104455" @default.
• W2553104455 workType "article" @default.